top of page

Know Labs, Inc. Reports Fourth Quarter and Fiscal Year 2023 Results

SEATTLE – Dec 19, 2023 – Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today reported financial results for the fourth quarter and fiscal year ended September 30, 2023. 


Financial Highlights:

  • Know Labs reported a net loss of $15.29 million dollars in FY2023, compared to a net loss of $20.07 million dollars in FY2022, a reduction in net loss of 23.8%. This translates to Earnings Per Share of a loss of $0.41, better than FY2022 Earnings Per Share Loss of $0.50, an improvement of 18%, before preferred stock dividends. 

  • In FY2023, recorded a non-cash charge to earnings of $4.77 million principally related to the fair market value of dividends on our Series C and D preferred stock in the amount of $2.96 million, that were either paid or accrued in shares of common stock, and the remaining $1.81 million non-cash charge comprised of $310,000 in depreciation & amortization, $550,000 loss on the sale of assets, $507,000 loss on debt extinguishment, $350,000 from the modification of notes and warrants and $142,000 from the amortization of operating lease right of use during FY 2023.

  • Research and development expense for FY2023 was $7.73 million dollars as compared to $5.39 million dollars in FY2022, an increase of 43.5% year over year. The increase in R&D expense was related to increases in engineering, third-party technical services, and expenditures related to the development of our Generation 1 device, which we completed and announced on June 7th, as we continue to execute our path to FDA clinical trials and commercialization.

  • Selling, general and administrative expenses for FY2023 was $6.57 million, which was lower by $1.55 million than the $8.12 million dollars in FY 2022, an improvement of 19.1%, as we continue our initiatives to reduce our cash burn.

  • As of September 30, 2023, we had cash and cash equivalents of $8.02 million dollars, as compared to $12.59 million at the end of September 30, 2022.  Net cash used in operations for FY2023 was $10.35 million dollars compared with $6.92 million in the prior year.  

  • During the year ended September 30, 2023, the Company made adjustments to its fixed expenses and the impact of those adjustments has significantly reduced our monthly burn rate.  Given the significant reduction in fixed expenses, the Company believes that it has enough available cash and flexibility with its operating expenses to operate until at least June 30, 2024.  As we have stated in our FY 2023 10-K, we expect to raise additional funds through the issuance of equity, preferred stock and convertible debentures. 

  • Shareholder equity for the fiscal year 2023 was $3.74 million versus $9.86 million in fiscal year 2022.

Income Statement:

Balance Sheet:

Cash Flow:

Conference Call: 


Know Labs will host an audio webcast to discuss its results and provide a business update today, December 19, 2023, at 4:30pm ET (1:30 pm PT). The live webcast will be available on the Investors page of the Company’s website,, and a replay will be available for six months. 


Participant Dial-In: 877-514-3621 / +1 215-268-9856


A copy of the form 10-K filed with the SEC can also be downloaded from the Company’s website. All holders, including stockholders and bondholders, can request and receive a hard copy of the complete audited financial statements free of charge. Requests must be submitted to


About Know Labs, Inc.

Know Labs, Inc. is a public company whose shares trade on the NYSE American Exchange under the stock symbol “KNW.” The Company’s platform technology uses spectroscopy to direct electromagnetic energy through a substance or material to capture a unique molecular signature. The technology can be integrated into a variety of wearable, mobile or bench-top form factors. This patented and patent-pending technology makes it possible to effectively identify and monitor analytes that could only previously be performed by invasive and/or expensive and time-consuming lab-based tests. The first application of the technology will be in a product marketed as a non-invasive glucose monitor. The device will provide the user with accessible and affordable real-time information on blood glucose levels. This product will require U.S. Food and Drug Administration clearance prior to its introduction to the market.


Safe Harbor Statement

This release contains statements that constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements appear in a number of places in this release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of Know Labs, Inc., its directors or its officers with respect to, among other things: (i) financing plans; (ii) trends affecting its financial condition or results of operations; (iii) growth strategy and operating strategy; and (iv) performance of products. You can identify these statements by the use of the words “may,” “will,” “could,” “should,” “would,” “plans,” “expects,” “anticipates,” “continue,” “estimate,” “project,” “intend,” “likely,” “forecast,” “probable,” “potential,” and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond Know Labs, Inc.’s ability to control, and actual results may differ materially from those projected in the forward-looking statements as a result of various factors. These risks and uncertainties also include such additional risk factors as are discussed in the Company’s filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended September 30, 2023, Forms 10-Q and 8-K, and in other filings we make with the Securities and Exchange Commission from time to time. These documents are available on the SEC Filings section of the Investor Relations section of our website at The Company cautions readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. The Company undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date on which such statement is made.


For Know Labs Media Inquiries Contact:

Matter Health

Abby Mayo

Ph. (617) 272-0592


Know Labs, Inc. Contact:

Jordyn Hujar

Ph. (206) 629-6414


Recent Posts

See All

Know Labs, Inc. Reports First Quarter FY2024 Results

SEATTLE – February 14, 2024 – Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today reported financial results for the first quarter ended De

bottom of page